NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
31 Mar 2020

AM-Pharma Increases Funding to €163m for Phase-III Trial of recAP in SA-AKI

AM-Pharma B.V., today announces that it has raised additional funds of €47m [US$52m], increasing the total recent fundraising to €163m [US$176m].
Aura Biosciences Presents Updated Phase 1b/2 Clinical Data for AU-011 at the 43rd Annual Macula Society Meeting<
24 Feb 2020

Aura Biosciences Presents Updated Phase 1b/2 Clinical Data for AU-011 at the 43rd Annual Macula Society Meeting

Light-Activated AU-011 Holds Significant Potential as a First Line Treatment for Choroidal Melanoma.
14 Feb 2020

Xeltis trials show promising function of living heart valves restored in children

Clinical trial results of Xeltis pulmonary valve (PV) show promising functionality of the living valves developed in patients as a result of its restorative implants.
13 Feb 2020

First patient dosed in pivotal phase 3 trial of SNF472 in calciphylaxis

Sanifit, today announced that the first patient has successfully been dosed in its pivotal phase 3 trial of the Company’s lead asset SNF472.
11 Feb 2020

CorWave Appoints Jim Schuermann as an Independent Director

CorWave, announced today the election of Jim Schuermann to its board of directors.
06 Feb 2020

Galecto Appoints Industry Leader Bertil Lindmark, MD, PhD, as Chief Medical Officer

Galecto, Inc., today announces the appointment of the highly experienced industry leader Bertil Lindmark as Chief Medical Officer per February 1, 2020.
09 Jan 2020

Minoryx Therapeutics receives US FDA fast-track designation for leriglitazone in the treatment of X-ALD

Minoryx Therapeutics, today announces that its lead drug candidate leriglitazone (MIN-102) has been granted fast track designation by the US Food and Drug Administration.

Aura Biosciences Appoints George Golumbeski, Ph.D., as Chairman of the Board of Directors<
07 Jan 2020

Aura Biosciences Appoints George Golumbeski, Ph.D., as Chairman of the Board of Directors

Former Celgene Business Development Head Brings Entrepreneurial Expertise and Life Science Business Leadership
07 Jan 2020

Galecto and PharmAkea merge to create strong clinical-stage company developing first-in-class therapeutics in fibrosis and cancer

Galecto and PharmAkea, Inc., today announced the two companies will merge.
04 Dec 2019

Anaconda biomed secures €20 million round of funding

Anaconda Biomed S.L., has closed €20 million in new funding.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка